Patents by Inventor Christine A. Franke

Christine A. Franke has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20050042756
    Abstract: The present invention provides two new chromosomal integration sites for expression of foreign genes have been developed in Streptococcus gordonii (S. gordonii). One integration site is intergenic between orfA and orfB in an operon of unknown function. The other site is intragenic within the lacG gene, which encodes phospho-?-galactosidase, and is part of the lactose (lac) operon. The emm6 gene from Streptococcus pyogenes was integrated in a stable configuration into the chromosome of S. gordonii at each of these integration sites, and in both cases the recombinant bacteria expressed the M6 protein on their surface. Furthermore, expression from the lacG site within the lactose operon was shown to be regulated by growth on lactose. Identification of these new chromosomal insertion sites provides the ability to express multiple foreign genes from the same recombinant and the potential for modulating expression in vitro or in vivo by the use of a biosynthetic metabolite.
    Type: Application
    Filed: November 3, 2003
    Publication date: February 24, 2005
    Inventors: Christine Franke, Tove Bolken, Kevin Jones, Dennis Hruby
  • Patent number: 6312955
    Abstract: The present invention features gram-positive bacteria resistant to 5-fluorodeoxyuridine (FUdR). Such bacteria will preferably be commensal, and will not be resistant to antibiotics. Bacteria according to the present invention may also be transformed with DNA encoding an antigenic protein. Such transformed bacteria may be used to formulate a vaccine, in order to stimulate an immune response to the antigenic protein in a patient. The present invention further provides a method for isolating gram-positive bacteria resistant to FUdR.
    Type: Grant
    Filed: April 29, 1999
    Date of Patent: November 6, 2001
    Assignee: Siga Pharmaceuticals
    Inventors: Dennis E. Hruby, Christine A. Franke
  • Patent number: 6306619
    Abstract: The DegP (HtrA) protease is a multifunctional protein essential for the removal of misfolded and aggregated proteins in the periplasm. The present invention provides an assay for inhibitors of DegP activity, comprising mixing a suspected inhibitor of DegP activity with DegP and a suitable substrate (preferably a native substrate of DegP such as PapA) and detecting changes in DegP activity. DegP has been shown to be essential for virulence in several Gram negative pathogens. Only three natural targets for DegP have been described: colicin A lysis protein (Cal), pilin subunits (K88, K99, Pap) and recently HMW1 and HMW2 from Hemophilus influenzae. In vitro, DegP has shown weak protease activity on casein and several other non-native substrates. The present inventors have identified the major pilin subunit of the Pap pilus, PapA, as a native DegP substrate and demonstrated binding and proteolysis of this substrate in vitro.
    Type: Grant
    Filed: June 29, 2000
    Date of Patent: October 23, 2001
    Assignees: Washington University, Siga Pharmaceuticals
    Inventors: Hal C. Jones, Christopher Liu, Scott J. Hultgren, Dennis E. Hruby, Christine A. Franke, Amy K. Evans